Marty and colleagues (Dec. 21 issue)1 found that letermovir prophylaxis after hematopoietic-cell transplantation resulted in a lower risk of clinically significant cytomegalovirus (CMV) infection than placebo. This trial shows that a prophylactic agent can provide meaningful benefit after hematopoietic-cell transplantation, without considerable myelotoxic events..
Letermovir Prophylaxis for Cytomegalovirus / Gentile, Giuseppe; Micozzi, Alessandra. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - ELETTRONICO. - 378:10(2018), pp. 964-965. [10.1056/NEJMc1800572]
Letermovir Prophylaxis for Cytomegalovirus
Gentile, Giuseppe
;Micozzi, Alessandra
2018
Abstract
Marty and colleagues (Dec. 21 issue)1 found that letermovir prophylaxis after hematopoietic-cell transplantation resulted in a lower risk of clinically significant cytomegalovirus (CMV) infection than placebo. This trial shows that a prophylactic agent can provide meaningful benefit after hematopoietic-cell transplantation, without considerable myelotoxic events..File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
Huillier_letermovir-prophylaxis_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
81.14 kB
Formato
Adobe PDF
|
81.14 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
